Johnson & Johnson's (NYSE:JNJ) med device segment had a pretty sleepy first quarter, with 0.7% revenue growth (about 1% operationally). But management highlighted some new and exciting opportunities for this underloved division, including a huge potential tailwind from the Affordable Care Act (also known as Obamacare). Watch the video below for more on this exciting growth opportunity.